Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,365 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Withdrawn Not applicable Interventional

Serial Screening and Treatment of Bacterial Vaginosis Trial

NCT05278130
View directory record Official record
Conditions
Bacterial Vaginosis, Preterm Delivery
Interventions
Additional vaginal swabs
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 24, 2026, 11:06 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

NCT06361836
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection

NCT00132457
View directory record Official record
Conditions
Chlamydia Infections
Interventions
Self-collected vaginal swab for chlamydia testing
Procedure
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years and older · Female only
Enrollment
1,830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
New Orleans, Louisiana • Jackson, Mississippi • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03561701
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 24, 2026, 11:06 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

ACE393-103 Vaccination Challenge Study

NCT00859716
View directory record Official record
Conditions
Campylobacter Infection
Interventions
ACE393, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2009 · Synced Oct 24, 2026, 11:06 AM EDT
Recruiting Phase 1 Interventional

Intestinal Microbiota Transplantation in Patients Undergoing Colon Resection

NCT06370884
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions
IMT
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

NCT00869336
View directory record Official record
Conditions
Tinea Pedis
Interventions
Luliconazole Cream 1% - 2 wks, Placebo Comparator -2 wks, Luliconazole Cream 1% - 4 wks, Placebo Comparator - 4 wks
Drug
Lead sponsor
Tinea Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fridley, Minnesota • Portland, Oregon • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 24, 2026, 11:06 AM EDT
Completed No phase listed Observational

Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department

NCT03131609
View directory record Official record
Conditions
Urinary Tract Infections, Bacteriuria, Urinalysis
Interventions
Container, Silver Impregnated Wipe, Funnel, Castile-soap wipe
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

NCT03450187
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional

Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy

NCT03213249
View directory record Official record
Conditions
Breast Implant Infection, Mammoplasty
Interventions
Normal saline, Cefazolin, Skin biopsy, Bilateral skin- or nipple-sparing mastectomies, Tissue expander, Breast implant, Autologous flap, Acellular dermal matrix sling, Gentamicin, Bacitracin
Other · Drug · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
rLP2086 vaccine, control
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
5,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 24, 2026, 11:06 AM EDT
Completed No phase listed Observational

Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis

NCT00620984
View directory record Official record
Conditions
Mastitis, Staphylococcus Aureus, Staphylococcal Infections
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older · Female only
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 24, 2026, 11:06 AM EDT
Terminated Phase 3 Interventional

Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

NCT00240747
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Synercid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
27 Weeks to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
6
States / cities
Oakland, California • Orange, California • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

NCT03565900
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Caspofungin, Normal Saline
Drug
Lead sponsor
Mycoses Study Group
Network
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

NCT02214433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 24, 2026, 11:06 AM EDT
Active, not recruiting Phase 2 Interventional

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

NCT05776004
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
CAL02, Placebo
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program

NCT02673255
View directory record Official record
Conditions
Healthy
Interventions
Tetanus and Diphtheria (Td) Vaccine
Biological
Lead sponsor
Biomat USA, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
4
States / cities
Bellflower, California • Lincoln, Nebraska • Clarksville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 24, 2026, 11:06 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

NCT03580044
View directory record Official record
Conditions
Serious Bacterial Infection
Interventions
ATM-AVI, BAT
Combination Product · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00607763
View directory record Official record
Conditions
Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
Interventions
Micafungin (Mycamine)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
4 Months to 23 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 24, 2026, 11:06 AM EDT
Terminated Phase 2 Interventional Results available

FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

NCT02255305
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
FMT, Antimicrobials
Biological · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 24, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 6 Years
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 24, 2026, 11:06 AM EDT